Wockhardt Recalls Lisinopril Tablets Due to Inadequate Complaint Investigation
Wockhardt USA is recalling specific lots of Lisinopril 5 mg tablets because the firm did not adequately investigate customer complaints.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, which typically indicates a temporary or medically reversible adverse health consequence. The specific cause is a CGMP deviation regarding complaint investigation, which is a procedural failure rather than a direct physical hazard like contamination or mislabeling, fitting the Moderate severity criteria for low-risk or procedural recalls.
Plain-English summary
Wockhardt USA Inc. is recalling Lisinopril Tablets USP, 5 mg, in 100, 500, and 1000 count bottles. The affected products are distributed nationwide, including Puerto Rico. The recall involves specific lot numbers and expiration dates ranging from April 2015 to February 2016.
The recall was initiated due to Current Good Manufacturing Practice (CGMP) deviations. Specifically, the firm did not adequately investigate customer complaints. This failure to investigate complaints is a regulatory compliance issue rather than a confirmed product defect or safety hazard.
Consumers with these specific lots of Lisinopril 5 mg tablets should contact their pharmacist or healthcare provider for guidance. The product is prescription-only, so patients should not discontinue medication without consulting their prescriber.
The recalled product
- Product
- Lisinopril Tablets USP, 5 mg Tablets,Packaged in A) 100 Count Bottles (NDC: 64679-928-01), B) 500 Count Bottles (NDC: 64679-928-05), and C) 1000 Count Bottles (NDC: 64679-928-06), Rx Only. Manufactured by: Wockhardt Limited, Mumbai, India. Distributed by: Wockhardt USA LLC 20 Wat
- Manufacturer
- Wockhardt Usa Inc.
- Category
- Drug — Antihypertensive
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- A) Lot #: DM10991
- Expiry: 4/30/2015
- Lot #: DM11226
- Lot #: DM11665
- Expiry: 6/30/2015
- Lot #: DM11810
- Lot #: DM12702
- Expiry: 9/30/2015
- Lot #: DN10719
- Expiry: 1/31/2016. B) Lot #: DM11651
- Lot #: DM11652
- Lot #: DM11664
- Lot #: DM12701
- Lot #: DN10139
- Expiry: 12/31/2015. C) Lot #: DM11041
- Lot #: DM11267
- Lot #: DM11268
- Lot #: DM11279
- Expiry: 5/31/2015
- Lot #: DM11286
Distribution
Part of a larger recall action
This product is one of 35 recalled by Wockhardt Usa Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 35 products in this recall →Related recalls
Same manufacturer · Wockhardt Usa Inc.
See all →- LowWockhardt Recalls Enalapril Maleate Tablets Due to Impurity Failures
FDA (Drugs) · 2017-11-01
- ModerateWockhardt Recalls Lisinopril Tablets Due to Inadequate Complaint Investigations
FDA (Drugs) · 2015-08-26
- ModerateWockhardt Recalls Lisinopril Tablets Due to Inadequate Complaint Investigations
FDA (Drugs) · 2015-08-26
- ModerateWockhardt Recalls Azithromycin Tablets Due to Complaint Investigation Failures
FDA (Drugs) · 2015-07-29
- ModerateWockhardt Recalls Zolpidem Tartrate Tablets Due to Complaint Investigation Failures
FDA (Drugs) · 2015-07-29
Same hazard · cgmp deviation
See all →- SevereZicam Cold Remedy Nasal Swabs Recalled for Microbiological Testing Failures
FDA (Drugs) · 2026-09-02
- ModerateGolden State Medical Supply Recalls Carbamazepine Tablets Due to CGMP Deviations
FDA (Drugs) · 2026-08-26
- SevereShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- ModerateShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- HighShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19